СOLORECTAL CANCER AND INCULIN-LIKE GROWTH FACTORS
https://doi.org/10.17650/2220-3478-2013-0-2-13-16
Abstract
Insulin-like growth factors (IGF) 1 and 2 and IGF binding proteins (IGFBP) 1 and 3 levels were measured by ELISA techniques in blood serum of 74 primary colorectal cancer (СRC) patients and 30 control practically healthy persons. Significant increase of IGF-1 level and decrease of IGFBP-3 level were demonstrated in patients’ serum as compared to control group. Sensitivity of IGF-1 as a prospective diagnostic СRС marker comprised 80 % with 75 % specificity using 140 ng/ml as cut-off level. Significant negative association was found be-tween both patients and donors’ age and serum IGF-1 levels, but in CRC patients it was much weaker than in control group. No associations were found between serum IGF 1 and 2 levels and main criteria of colorectal cancer progression.
About the Authors
A. A. Nikolayev
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
E. S. Gerstein
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
E. A. Korotkova
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
V. V. Delektorskaya
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
E. K. Dvorova
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
References
1. Костылева О.И., Герштейн Е.С., Дигаев а М.А. и др. Инсулиноподобные факторы роста, их рецепторы и связывающие белки как патогенетические факторы и потенциальные мишени терапии в онкологии. Вопросы биологической, медицинской и фармацевтической химии 2009;6:3–8.
2. Durai R., Yang W., Gupta S. et al.The role of the insulin-like growth factor system in colorectal cancer: review of current knowledge. Int J Colorectal Dis 2005;20(3):203–20.
3. Koda M., Reszec J., Sulkowska M. et al. Expression of the insulin-like growth factor-I receptor and proapoptotic Bax and Bak proteins in human colorectal cancer. Ann NY Acad Sci 2004;1030:377–83.
4. Fu P., Thompson J.A., Leeding K.S., Bach L.A. Insulin-like growth factors induce apoptosis as well as proliferation in LIM 1215 colon cancer cells. J Cell Biochem 2007;100(1):58–68.
5. Yavari K., Taghikhani M., Maragheh M.G. et al. Knockdown of IGF-IR by RNAi inhibits SW480 colon cancer cells growth in vitro. Arch Med Res 2009;40(4):235–40.
6. Davies M., Gupta S., Goldspink G., Winslet M. The insulin-like growth factor system and colorectal cancer: clinical and experimental evidence. Int J Colorectal Dis 2006;21(3):201–8.
7. Vrieling A., Voskuil D.W., Bosma A. et al. Expression of insulin-like growth factor system components in colorectal tissue and its relation with serum IGF levels. Growth Horm IGF Res 2009;19(2):126–35.
8. Sztefko K., Hodorowicz-Zaniewska D., Popiela T., Richter P. IGF-I, IGF-II, IGFBP2, IGFBP3 and acid-labile subunit (ALS) in colorectal cancer patients before surgery and during one year follow up in relation to age. Adv Med Sci 2009;54(1):51–8.
9. Bustin S.A., Dorudi S., Phillips S.M. et al. Local expression of insulin-like growth factor-I affects angiogenesis in colorectal cancer. Tumour Biol 2002;23(3):130–8.
10. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 2001;131(Suppl 11): 3109–20.
11. Jenab M., Riboli E., Cleveland R.J. et al. Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2007;121(2):368–76.
12. Park J.H. Inhibition of colon cancer cell growth by dietary components: role of the insulin-like growth factor (IGF) system. Asia Pac J Clin Nutr 2008;17(Suppl 1):257–60.
13. Nomura A.M., Stemmermann G.N., Lee J., Pollak M.N. Serum insulin-like growth factor I and subsequent risk of colorectal cancer among Japanese-American men. Am J Epidemiol 2003;158(5):424–31.
14. Rinaldi S., Cleveland R., Norat T. et al. Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies. Int J Cancer 2010;126(7):1702–15.
15. Bruchim I., Werner H. Targeting IGF-1 signaling pathways in gynecologic malignancies. Expert Opin Ther Targets 2013;17(3):307–20.
16. Mitsiades C.S., Mitsiades N.S., McMullan C.J. et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004;5(3):221–30.
17. Perer E.S., Madan A.K., Shurin A. et al. Insulin-like growth factor I receptor antagonism augments response to chemoradiation therapy in colon cancer cells. J Surg Res 2000;94(1):1–5.
18. Maloney E.K., McLaughlin J.L., Dagdigian N.E. et al. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 2003;63(16):5073–83.
19. Vanamala J., Reddivari L., Radhakrishnan S., Tarver C. Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways. BMC Cancer 2010;10:238.
20. Leng S.L., Leeding K.S., Whitehead R.H., Bach L.A. Insulin-like growth factor (IGF)-binding protein-6 inhibits IGF-II-induced but not basal proliferation and adhesion of LIM 1215 colon cancer cells. Mol Cell Endocrinol 2001;174(1–2):121–7.
21. Alami N., Page V., Yu Q. et al. Recombinant human insulin-like growth factor-binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models. Growth Horm IGF Res 2008;18(6):487–96.
Review
Views:
892
Email this article 